Rebiotix announced that it has developed a new metric designed to identify indicators for microbiome restoration, according to a press release.
The company developed the Microbiome Health Index (MHI) in a partnership with the data analytics firm BioRankings to provide the research community with a standardized tool to measure rehabilitation of the human microbiome, according to the press release.
“In developing the Microbiome Health Index, our aim is to provide an objective, universal tool to measure the restoration of a dysbiotic microbiome across different trial designs, sequencing methods and across multiple drug technologies,” Ken F. Blount, PhD, chief scientific officer of Rebiotix, said in the press release. “Initial analyses using MHI in Clostridium difficile infections have demonstrated its significant potential to quantify and differentiate dysbiotic from healthier microbiomes.”
MHI tracks changes in four taxonomic classes known to be important to microbiome health and colonization resistance — Bacteriodia, Clostridia, Gammaproteobacteria and Bacilli. Using the metrics, researchers were able to differentiate between patients with a microbial imbalance and healthy patients in a study of Rebiotix’s microbiota drug RBX2660, per the press release.
“The human microbiome is a new frontier where very little analytical methodology or rigorous statistical methods have been developed specifically for this type of data,” Bill Shannon, PhD, MBA, co-founder and managing partner of analytics at BioRankings said in the press release. “Analytical tools such as MHI will be critical to advance translational clinical microbiome research, and we are emboldened by the MHI data that have been reported and continuing to be collected. Our vision is for MHI to become a standard measure for microbiome research, potentially serving as a validated endpoint for clinical trials and providing both a predictive measure and actionable data.”
Disclosures: Blount is employed by Rebiotix. Shannon is employed by BioRankings.